Effects of mithramycin and calcitonin in cardiovascular complications of Paget's disease of bone
Pembrook, R.C.; Chung, C.H.; Carvallo, A.P.
Connecticut Medicine 39(4): 209-214
1975
ISSN/ISBN: 0010-6178 PMID: 125180 Document Number: 91071
Document emailed within 1 workday
Related Documents
Luboshitzky, R.; Bar-Shalom, R. 1995: Calcitonin nasal spray for Paget's disease of the bone Harefuah 128(6): 358-362; 399Manderlier, T.; Fuss, M.; Brauman, J.; Orloff, S.; Bergans, A.; Corvilain, J. 1976: Treatment of Paget's disease of bone with salmon calcitonin Acta Clinica Belgica 31(6): 329-338
Tarquini, B.; Ciapini, A.; Benvenuti, M.; Moretti, R.; Cherici, R.; Comparini, T.; Neri, B. 1980: Chronopharmacological effect of porcine calcitonin in Paget's disease of the bone La Clinica Terapeutica 94(6): 659-670
Epstein, S. 1974: Mithramycin in Paget's disease South African Medical Journal 48(31): 1328-1330
Dube, W.J.; Goldsmith, R.S.; Arnaud, S.B.; Arnaud, C.D. 1973: Development of antibodies to porcine calcitonin during treatment of Paget's disease of bone Mayo Clinic Proceedings 48(1): 43-46
Epstein, S.; Owen, G. 1977: Paget's disease of bone (osteitis deformans) treated with human synthetic calcitonin South African Medical Journal 51(5): 133-137
Eisinger, J.; D'Omezon, Y.; Recordier, A.M. 1973: Mithramycin in the treatment of hypercalcemia and Paget's disease Revue du Rhumatisme et des Maladies Osteo-Articulaires 40(6): 457-460
Chakravorty, N.K. 1985: Neurological complications of Paget's disease of bone British Journal of Clinical Practice 39(9): 335-338
Louyot, P.; Pourel, J. 1974: Paget's disease and calcitonin. Personal experience Acta Orthopaedica Belgica 40(4): 538-545
Renier, J.C.; Boasson, M.; Jallet, P.; Bernat, M. 1973: Short term treatment of Paget's disease with porcine calcitonin Revue du Rhumatisme et des Maladies Osteo-Articulaires 40(10): 557-563
Ghiringhelli, G.; Fogel, M.; Varela de Rodríguez, J.; Casco, C.; Mautelén, C.; Nusimovich, B. 1982: Treatment of Paget's disease with the combined administration of calcitonin and disodium etidronate Medicina 42(1): 16-20
Wenz, W.; Basler, L. 1985: Significance of x-ray diagnosis in the control of calcitonin therapy of Paget's disease: case report Der Radiologe 25(12): 594-596
Courvoisier, B.; de Barros, Q.; Jacot, C.; Zender, R. 1970: Acute effect of porcine calcitonin in persons without osteopathy and patients with Paget's disease Schweizerische Medizinische Wochenschrift 100(1): 26-32
Miravet, L.; Kuntz, D. 1989: Amino-hydroxy-propylidene biphosphonate in the treatment of Paget's disease resistant to calcitonin and/or etidronate Revue du Rhumatisme et des Maladies Osteo-Articulaires 56(4): 287-292
Detilleux, M.; Guillausseau, P.J.; Caquet, R.; Reynaud, M.; Metzger, J.; Askienazy, S.; Laroche, C. 1977: Paget's disease with obstructive communicating hydrocephalus and dementia. Favorable outcome under the treatment with calcitonin Annales de Medecine Interne 128(8-9): 667-672
Heuer, L.J.; Wassmann, L.; Wood, W.G. 1984: Comparative studies of the effect of mithramycin and calcitonin on small intestine and pancreas function in the rat Deutsche Zeitschrift für Verdauungs- und Stoffwechselkrankheiten 44(2): 45-49
Lo Cascio, V.; Lechi, C.; Adami, S.; Bianchi, I.; Cominacini, L.; Galvanini, G. 1974: Comparative studies of the behavior of blood calcium and urinary hydroxyproline after infusion of calcitonin and glucagon in patients with Paget's disease Bollettino della Societa Italiana di Biologia Sperimentale 50(1-2): 55-61
Burkman, R.T. 1994: Noncontraceptive effects of hormonal contraceptives: Bone mass, sexually transmitted disease and pelvic inflammatory disease, cardiovascular disease, menstrual function, and future fertility American Journal of Obstetrics and Gynecology 170(5 Pt 2): 1569-1575
Yoshikawa, S. 1986: Etiology and pathology of metabolic bone diseases: Paget's disease of bone and osteosclerosis Nihon Rinsho. Japanese Journal of Clinical Medicine 44(11): 2437-2442
Farre, J.M.; Delcambre, B. 1989: Functional consequences and complications of Paget's disease La Revue du Praticien 39(13): 1129-1136